Isoniazid: Clinical Trials

61 trials of Isoniazid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 9 recruiting, 7 terminated, 6 not yet recruiting. 61 Phase 2, 13 Phase 3, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 261Completed 29, Recruiting 9, Terminated 7, Not yet recruiting 6, Active not recruiting 4, Unknown 4, Suspended 2
Phase 313Completed 8, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1
Phase 18Completed 6, Active not recruiting 1, Recruiting 1

Follow Isoniazid: new trials by email Literature Review of Isoniazid trials Research Report on Isoniazid

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Re-evaluating the Duration in Children of TB Treatment
Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis
Phase 2Not yet recruitingUniversity of Wisconsin, Madison2302027-02-012026-11-02
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Isoniazid, Rifampin, Pyrazinamide - Tuberculosis
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)9002026-10-302026-08-19
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Rifapentine, Isoniazid, Dolutegravir - Tuberculosis
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)1442026-09-282026-11-02
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary
Phase 2Not yet recruitingTASK Applied Science1352026-09-252026-09-25
AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT
Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis
Phase 2Not yet recruitingMinistry of Health, Saudi Arabia2002026-09-012026-03-12
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent
Phase 2 / Phase 3RecruitingJohns Hopkins University25302026-05-082026-10-20
ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)
Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB)
Phase 2RecruitingObafemi Awolowo University Teaching Hospital802026-01-032026-01-23
Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) - Pulmonary Tuberculoses
Phase 2RecruitingThirty Respiratory Limited242025-10-132026-01-12
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis
Phase 2Not yet recruitingShanghai Pulmonary Hospital, Shanghai, China452025-08-202025-08-19
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
Rifampin, Isoniazid, Rifapentine (RPT) - Mild Spinal Tuberculosis
Phase 2Not yet recruitingShandong University3002025-04-052025-04-08
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis
Phase 2SuspendedNational Institute of Allergy and Infectious Diseases (NIAID)3412025-03-112026-11-02
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis
Phase 2RecruitingTASK Applied Science602025-03-032025-03-07
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy
Phase 1 / Phase 2Active not recruitingThe Aurum Institute NPC2522024-01-172025-12-12
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis
Phase 2RecruitingUniversity College, London25002024-01-092026-10-15
ATORvastatin in Pulmonary TUBerculosis
Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis
Phase 2RecruitingObafemi Awolowo University Teaching Hospital4402024-01-032025-09-25
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD) - Tuberculous Meningitis
Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)3302023-12-072026-11-18
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis
Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV
Phase 2Active not recruitingBrigham and Women's Hospital942023-11-242026-08-05
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection
Phase 2 / Phase 3Active not recruitingCenters for Disease Control and Prevention2882023-11-212026-09-21
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis
Phase 2Active not recruitingGlobal Alliance for TB Drug Development3092023-10-312026-06-24
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis
Phase 2TerminatedGates Medical Research Institute932023-07-262026-05-20

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Tuberculosis (36)  ·  Tuberculosis, Pulmonary (27)  ·  HIV Infections (7)  ·  Latent Tuberculosis (5)  ·  Tuberculosis, Multidrug-Resistant (5)  ·  Tuberculosis, Meningeal (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Asthma (1)  ·  Central Nervous System Diseases (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Extensively Drug-Resistant Tuberculosis (1)  ·  Gram-Positive Bacterial Infections (1)  ·  HIV Seropositivity (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Pneumonia, Pneumocystis (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (11)  ·  Centers for Disease Control and Prevention (5)  ·  Johns Hopkins University (4)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3)  ·  Global Alliance for TB Drug Development (3)  ·  Michael Hoelscher (3)  ·  Obafemi Awolowo University Teaching Hospital (3)  ·  TASK Applied Science (3)  ·  University College, London (2)  ·  University of Cape Town (2)  ·  Amphastar Pharmaceuticals, Inc. (1)  ·  Brigham and Women's Hospital (1)  ·  Dance Biopharm Inc. (1)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  GSVM Medical College (1)

Countries

South Africa (32)  ·  Uganda (15)  ·  Haiti (10)  ·  Tanzania (9)  ·  Brazil (8)  ·  Malawi (8)  ·  Philippines (8)  ·  United States (8)  ·  Kenya (7)  ·  Thailand (7)  ·  Zimbabwe (7)  ·  India (6)  ·  Peru (6)  ·  Vietnam (6)  ·  Botswana (5)

Top investigators

Bolanle A Omotoso, MD (3)  ·  Kelly Dooley, MD, PhD (2)  ·  Marc Weiner, MD (2)  ·  Nicholas Paton (2)  ·  Olanisun O Adewole, MD (2)  ·  Susan Dorman, MD (2)  ·  Andreas Diacon, MD, PhD (1)  ·  Andreas Diacon, Prof (1)  ·  Andreas H Diacon, MD, PhD (1)  ·  Anneke Hesseling, MD (1)  ·  Anthony Garcia-Prats, MD, MSc, PhD (1)  ·  Anthony Podany, PharmD (1)  ·  Avy Violari, MD (1)  ·  Charles D. Mitchell, MD (1)

Results publications

PMID 33542052, PMID 36808186, PMID 38768617, PMID 15844071, PMID 16776446, PMID 17517835, PMID 18070980, PMID 18230259, PMID 18787216, PMID 19406981, PMID 19564361, PMID 19923475, PMID 20607114, PMID 20660695, PMID 21494548, PMID 21732834, PMID 23433590, PMID 24663014, PMID 26872154, PMID 27159505, PMID 27550361, PMID 28100438, PMID 28739794, PMID 29463526, PMID 29528048, PMID 29584861, PMID 30102705, PMID 31732485, PMID 31932382, PMID 31945300, PMID 31969368, PMID 32564076, PMID 33229425, PMID 33508224, PMID 33834177, PMID 34323955, PMID 34403326, PMID 35175905, PMID 35273049, PMID 35291004, PMID 35315690, PMID 35607710, PMID 36455068, PMID 36966799, PMID 38243296, PMID 38564365, PMID 38568956, PMID 39622823, PMID 39651910, PMID 39793592

NIH funding

U01AI068636 (2), 2019 (1), R01HD074944 (1), U01AI068632 (1), U01AI134585 (1), U01AI170426 (1), U01AI192041 (1), UM1AI068636 (1)